Clinical Trial: Intestinal Microbiome and Chemotherapy
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Chemotherapy-driven Dysbiosis in the Intestinal Microbiome
Brief Summary:
Chemotherapy is commonly used as myeloablative conditioning treatment to prepare patients for haematopoietic stem cell transplantation (HSCT). Chemotherapy leads to several side effects, with gastrointestinal (GI) mucositis being one of the most frequent. Current models of GI mucositis pathophysiology are generally silent on the role of the intestinal microbiome.
The aim of the study is to identify functional mechanisms by which the intestinal microbiome may play a key role in the pathophysiology of GI mucositis, the investigators applied high throughput DNA-sequencing analysis to identify microbes and microbial functions that are modulated following chemotherapy.
Detailed Summary:
Sponsor: Nantes University Hospital
Current Primary Outcome:
- analyze of the fecal samples using 16S ribosomal ribonucleic acid (rRNA) gene sequencing [ Time Frame: baseline ]
- analyze of the fecal samples using 16S ribosomal ribonucleic acid (rRNA) gene sequencing [ Time Frame: at day 7 ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Nantes University Hospital
Dates:
Date Received: August 18, 2016
Date Started: November 2010
Date Completion:
Last Updated: August 26, 2016
Last Verified: August 2016
